# Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

> **NCT06830031** · PHASE1 · RECRUITING · sponsor: **Shanghai Exuma Biotechnology Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Diffuse Large B-cell-lymphoma
- DLBCL, Nos Genetic Subtypes
- Follicular Lymphoma Grade 3B
- PMBL
- HGBL With MYC and BCL2 and/or BCL6 Rearrangements
- HGBL, Nos

## Interventions

- **BIOLOGICAL:** C402-CD19-CAR

## Key facts

- **NCT ID:** NCT06830031
- **Lead sponsor:** Shanghai Exuma Biotechnology Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-19
- **Primary completion:** 2026-03-09
- **Final completion:** 2026-05-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830031, "Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06830031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*